1 Article

2 Assessment of Attitude and Hesitancy Towards Covid-19 Vaccine among

- Hepatitis B and C Patients in Pakistan
 4
- 5 Short Title: Refusal to covid-19 vaccine among viral Hepatitis patients in Pakistan
- 6
- 7 Farheen Shafiq¹,
- 8 https://orcid.org/0000-0003-3658-9729
- 9 Mahreen ul Hassan²*
- 10 <u>https://orcid.org/0000-0002-5524-9765</u>
- 11 Sadia Butt³
- 12 <u>https://orcid.org/0000-0002-3631-3354</u>
- 13 Sadia sidique⁴
- 14 <u>https://orcid.org/0000-0001-6483-3579</u>
- 15 Nazia Akbar⁵
- 16 <u>https://orcid.org/0000-0003-2203-4933</u>
- $17 \quad \text{Azra}^6$
- 18 <u>https://orcid.org/0000-0002-3088-2345</u>
- 19 Irshad Rehman⁷
- 20 https://orcid.org/0000-0002-2724-6946
- 21
- 22 *Correspondence:
- 23 Dr. Mahreen ul Hassan
- 24 https://orcid.org/0000-0002-5524-9765
- 25 Email:microkust@sbbwu.edu.pk
- 26 Contact no.03348483041
- 27 78 Western Bank
- 28 Firth Court
- 29 Department of Bioscience
- 30 University of Sheffield, UK
- 31 S10 2TN
- 32 Sheffield, South Yorkshire
- 33 United Kingdom

34 ABSTRACT

OBJECTIVE: The research aimed to evaluate the attitude and perceptions towards the covid-19
 vaccine among Hepatitis B and C patients in Peshawar, Khyber Pakhtunkhwa, Muzaffarabad,
 Azad Kashmir, Pakistan.

METHODS: A survey-based study was adopted to evaluate the attitude of Hepatitis B and C patients towards immunization against covid-19 in Peshawar (KPK) and Muzaffarabad (AJK) cities of Pakistan. The study continued from January 2020 to February 2021. Participants were also assessed for their perception towards covid-19 vaccination.

42 **RESULTS:** A total of 839 (33.6%) individuals participated in the study. About 52 % of Hepatitis B patients were immunized against Covid-19, whereas the number of Hepatitis C 43 patients was recorded at around 48%. About 53.7 % of participants refused to get the vaccine 44 45 without any reason. About 63.2% of patients showed concern about the insufficient data available on the vaccine safety and efficacy published by the Public Health Department. 46 Individuals with higher education were observed to be more open towards vaccination then those 47 without a formal education. More than half of the participants (61.5 %) were concerned about the 48 interference of the vaccine with their hepatitis treatment whereas 54.7 % patients refused vaccine 49 50 because of a poor liver condition.

51 **CONCLUSIONS:** The data indicated that limited data availability regarding the vaccine 52 efficacy in viral hepatitis patients and negative attitudes of people toward covid-19 vaccination is 53 the main cause of Covid-19 vaccination refusal among hepatitis B and C patients.

54 **DESCRIPTORS:** Hepatitis B, Hepatitis C, covid-19, immunization, vaccine refusal, Pakistan.

55 **INTRODUCTION**

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the 7th human coronavirus, was reported in Wuhan, Hubei province, China, in January 2020¹⁻². In early 2020, the World Health Organization (WHO) declared it a pandemic and requested the world to take strict measures to control the disease as there was no effective treatment available, and the death toll was rising every hour across the world³.

The SARS-CoV-2 is an airborne virus which can be transmitted through air therefore effective preventive measures like social distancing, frequent handwash and wearing a mask in the absence of a valid treatment or vaccine to control the disease was imperative⁴.

Patients with covid-19 may have abnormal liver function or hepatic dysregulation, which may identify as cholestasis, hepatitis, or both. In an early study from China, increased total bilirubin was observed in 18 (18%) patients and higher serum alanine aminotransferase (ALT) was recorded in 28 (28%) of 99 individuals with covid-19⁵.

It is suggested that SARS-CoV-2 may exacerbate liver damage in individuals with chronic viral hepatitis⁶. According to Xu et al.⁷ (2020), liver dysfunction occurs more often and more severely as covid-19 progresses. Liver function tests are typically normal or somewhat raised in the early stages of SARS-CoV-2 infection. Histological examination of the liver reveals syncytial multinuclear hepatocytes, microvascular steatosis, and little lobular and portal activity.

The cytokine storm caused by the progression of severe covid-19 cases requiring strong immunosuppressive therapy has raised the problem of recurrence of HBV infections in the patients with a history of HBV^8 .

In a study conducted by Ronderos et al.⁹ (2021), patients with covid-19 having history of hepatitis C virus (HCV) or seropositivity for HCV infection have an increased susceptibility to SARS-CoV-2 infection, which is a strong predictor of in-hospital mortality regardless of preexisting conditions, laboratory results upon admission, or the severity of covid-19-induced liver injury.

With an estimated 9.8 million chronic HCV patients, Pakistan has the second-highest burden of HCV infection in the world¹⁰. Unscreened blood transfusions, a history of hospitalization, dental work, tattooing, body piercing, the use of injections, and a history of surgery are the main risk factors for the transmission of HCV¹¹. According to government statistics, around 2.5% of Pakistan's population was infected with HBV in 2008. There was a 5% rise in HCV-related mortality and an 8% increase in HBV-related deaths between 2015 and 2019¹⁰.

According to World Health Organization vaccination is an easy, safe, and efficient way to avoid infection especially in the absence of an effective therapy as in the case of covid-19¹².

Vaccination is the most significant medical intervention in the human history which has largely eradicated the infectious diseases that formerly claimed the lives of millions of people¹³. Currently, more than 30 infectious diseases could be avoided with the use of vaccinations¹⁴. According to an estimation, the immunization against covid-19 have prevented thousands of deaths and saved millions of people from getting infection in England and United States till June 2021¹⁵⁻¹⁶.

Pakistan is also badly affected by covid-19 pandemic. Currently there are 1,573,922 confirmed
covid-19 cases from which 2,928 are marked as active in different areas of Pakistan and about
30,625 causalities have been observed from 2020 to date¹⁷.

98 The Chinese government sent more than 500,000 doses of the Chinese Sinopharm vaccine to Pakistan in February 2021, and the Pakistani government opted to prioritize immunizing 99 frontline healthcare workers¹⁸. Pakistan initially restricted immunization to those aged 18 and 100 older before expanding the program. The government was placing a higher priority on heavily 101 102 populated metropolitan centers and "hotspot" locations, where the coronavirus transmits more rapidly than in more distant rural communities¹⁹. It is estimated that about 69.9 % population in 103 104 Pakistan has taken at least on dose of covid-19 vaccine. The number is not very discouraging but nature of disease and its transmission along with the emergence of new Corona virus variants 105 106 every 6 month makes it crucial to get the entire population immunized in limited time to control the disease 17 . 107

Vaccine hesitancy is one of the top 10 global health problems, according to the World Health Organization²⁰. Fear of the covid-19 vaccination is a growing problem that Pakistan is also dealing with. It is one of the nations with lowest vaccination rates²¹. Myths such as the vaccine causes sterility, the pandemic is a foreign conspiracy, or the virus is harmless are common contributors to the hesitation towards covid-19 vaccination²².

In current study have sought to understand the current level of awareness of covid-19 transmission, symptoms, and preventive measures specifically among Hepatitis B and C patients. The study also aimed to identify the risk variables that contribute to ambivalence towards covid-19 vaccination among hepatitis patients residing in KPK and AJK, Pakistan.

117 METHODOLOGY

118 Study Location and Settings

119 Survey-based research was conducted in Peshawar and Muzaffarabad from January 2020 to 120 February 2021. A questionnaire was prepared for the study. An epidemiologist, field surveyor, 121 and health care practitioner assisted in the development of a questionnaire. To calculate the 122 reliability score and Cronbach alpha, the questionnaire was pretested in a pilot study.

123 Sample Size and Exclusion Criteria

For the evaluation of the knowledge and perception of the hepatitis B and C patients toward covid-19 and the vaccination program the questionnaire was distributed throughout the community where these patients were easily accessible. Hepatitis B and C patients age 18 years and above were deemed eligible. Participants who refused to provide any information or who were temporary residents were barred from participating. The questionnaire was created to identify potential challenges to covid-19 immunization.

130 **Designing and Validating the Questionnaire**

Following a thorough review of the relevant literature, a questionnaire was designed. It was composed in English, then translated into Urdu and Pushto for participants before translated back to English for analysis. The questionnaire was divided into two sections, each with 16 questions. Section one had ten questions that assessed demographic data such as age, gender, race, income, marital status, and so on. The next section included 16 questions designed to test participants' knowledge and perceptions about covid-19 and its vaccination.

137 Statistical Analysis

138 Data evaluation was performed through SPSSv21 statistical package.

139 Ethical Approval and Consent of Participants

140 This study was approved by the Research and Ethics Committee of Shaheed Benazir Bhutto 141 Women University Peshawar, Pakistan. A filled and signed informed consent form was collected 142 from each participant before the participation. All the information of the participants is kept 143 confidential.

144 **RESULTS**

145 **Demographic Details of the Respondents**

A total of 839 responses were collected, of which 36.1% (303) were female and 63.9% (536) 146 147 were from male respondents. Table 1 displays the demographic data (age, gender, place of residence, educational background, occupation, and monthly income) of the survey respondents. 148 149 About 48% responses were collected from Hepatitis B patients whereas the response rate of Hepatitis C patients was 52 %. Age-wise most of the patients were young (57.1%) while it was 150 observed that the number of respondents were mostly male (63.9 %) that could be due to the 151 152 cultural barriers in the area. The data generated through this study revealed the about 35.5% 153 hepatitis patients were still unvaccinated due to various reasons.

154 Table 1. shows demographic data frequencies of the participants. (n = 839).

155 Approved Vaccines in Pakistan

156 In Pakistan, every person above age 18 was bound to get one of the approved Covid-19 vaccines to minimize the devastating effects of pandemic according to National Action Plan for Corona 157 virus disease (covid-19) Pakistan^a (Table S1). For the purpose, Government of Pakistan worked 158 tirelessly making the best vaccines widely available to the public. As a result, about 10% of the 159 population received the first by the mid of year 2021. The information presented in Table 6 was 160 generated as a secondary data by utilizing all the reliable resources available e.g., National 161 Institute of Health Pakistan^b, WHO^c and dedicated website for covid-19 related information by 162 the Ministry of National Health Services Pakistan^d. Likewise, it was advised that everyone with a 163 known underlying disease, including those with hepatitis, immunize themselves against covid-164 19. 165

166 Table 2- Commercially available Vaccines approved by the Government of Pakistan.

It was observed during the study that around 65 % participants were fully immunized (Figure
1a), and rest of the participants refused after taking first dose to immunize due to some reasons
(Figure 1b).

^a <u>https://www.nih.org.pk/wp-content/uploads/2020/04/COVID-19-NAP-V2-13-March-2020-1.pdf</u>

https://www.nih.org.pk/public/novel-coranavirus-2019-ncov

^c <u>https://covid19.who.int/region/emro/country/pk</u>

d <u>https://covid.gov.pk/</u>

Figure 1a. No. of patients receiving covid-19 vaccines from approved pharmaceuticals. b. No. of Patients refused to get immunized.

The main objective of this study was to evaluate the hepatitis patients' awareness of the covid-19 vaccination and the fears that were keeping them from receiving the vaccine. For the purpose a derailed interview was arranged with each participant and their answer were recorded for further analysis.

176 Attitude and Perceptions towards covid-19 vaccination

- The questionnaire was split in two parts i.e., part A (Table 3a) where patients were assessed why they chose to get immunized against covid-19. Part B (Table 3b) was specifically designed for
- The they chose to get minumized against covid 17. Part D (Pable 50) was specifically designed F
- the patients who refused to take covid vaccine.

The questionnaire A analysis revealed that most participants (79.5%) were happy to get 180 181 vaccinated because there were no charges of that vaccine as compared to the Hepatitis C vaccine 182 available in the markets (Table 3a). Many participants (76.9%) believed that the vaccine would protect them from covid-19. About 76.5% people claimed that thy were encouraged when they 183 realized that other hepatitis patients were also getting vaccine. As a reflection of their confidence 184 in their doctors, 469 out of 710 people (71.2% of the total) vaccinated themselves after medical 185 186 professionals encouraged them to do so. Yet 374 (56.8%) patients showed concern about the 187 insufficient data available on the vaccine safety and efficacy published by the Public Health Department. 188

Table 3a. Assessment of patients choosing covid-19 vaccine for protection. b. Question statements to assess Hepatitis patient for refusing covid-19 vaccine.

There were many explanations given by individuals when asked why they didn't want to be 191 192 vaccinated (Table 3b). About 74.1 % of participants had a view that precautionary measures like 193 social distancing and wearing a mask or visor could protect them from getting coivd-19 194 infection. Some people refused (63.2 %) to get vaccination simply because they did not have enough information about the vaccine due to unavailability of literature regarding outcomes of 195 196 covid vaccination. Interestingly, half of the patients (53.7 %) were simply against any type of immunization whatever vaccine it was and perceived the immunization as a part of foreign 197 198 agenda. However, 181 (61.5 %) patients were worried that the vaccine might interact with their 199 hepatitis therapy as there is no published data available which can prove it wrong; people don't

200 believe in assumptions especially in case of a health-related issue. The study also revealed that 201 about 54.7 % of total participants were concerned about their liver condition as they were already 202 dealing with a liver infection. The fear of an over-burdened liver cannot be overlooked. More than half (57.5 %) of the patients who were against the vaccination were of view that there is no 203 point to get vaccination if it is not protecting you against the infection. Around 58.5 % 204 participants were of view that they have immunity against the disease due to the previous covid 205 206 infection. Unfortunately, some patients (12.2 %) got allergic reactions after getting first dose due to which they feared to try another type of covid vaccine. 207

208 **Correlation between various parameters**

209 Table 4a showed positive and negative correlation between various parameters of hepatitis patients with respect to the trend towards covid-19 vaccine. A very strong relationship (.104**) 210 211 was found among the self-employed people toward the covid vaccine as compared to the people 212 related to other sources of income. The trend showed that there was a significant difference 213 among the people of various education levels. The participants having higher levels of education 214 were more agreed to get vaccinated against covid-19 as compared to others. Surprisingly, participants having high incomes were showed a highly significant difference and were less 215 likely to get vaccinated (-.119**) and same was the trend seen in case of females (-0.018). All 216 217 age groups showed a weak relationship between patients and their attitude towards the covid vaccine. A negative correlation was seen in case of ethnicity and location. It was revealed that 218 participants from Punjabi origin were reluctant (-0.064) to get vaccinated as compared to 219 220 Kashmiri and Pathans. The study also revealed that less people from Muzaffarabad AJK were get vaccinated (-0.022) than those from Peshawar, KPK. 221

Table 4a. Correlation between different variables of Hepatitis B and C patients with the covid-19 vaccine approval or rejection. b. Spearman correlation between different variables and covid-19 vaccine.

225 Relationship between Demographic Characteristics and Responses of Participants

Associations of different characteristics were made against the participants' knowledge of covid-19 (Table 4b). First, education levels of the participants were evaluated against the use of mask by the participants. It was observed that the use of mask was significantly less among individuals with lower education levels as compared to individuals with higher education (P 0.064).

230 However, non-significant relationships were present between education level and other aspects of our study such as attending social gatherings, frequent hand washing, and covid-19 as a 231 232 bioweapon. Second, income levels of the participants were analyzed against various factors. A significant relationship was found among the income level of the participant and their affinity to 233 234 join social gatherings during the covid-19 pandemic. It was observed that respondents with lower income levels were more likely to attend gatherings as compared to higher income respondents. 235 236 Similarly, income level was also found to be associated with the subjects' use of mask. Participants with higher income levels were wearing N95 and surgical masks, whereas cloth 237 masks were usually used by lower-income respondents. Terminally higher- and lower- income 238 category subjects wore fewer masks as compared to middle-income-range groups. More 239 240 participants in the lower-income category had to leave their jobs or had their business shut down during the covid-19 pandemic as compared to higher-income respondents. Likewise, more 241 women have left their jobs as compared to their male counterparts. However, business shutdown 242 trend mainly affected the male gender. Moreover, the males were found to wear mask more often 243 than the females. Females usually wore N95 masks, whereas male respondents relied more on 244 surgical masks or cloth masks. On the contrary, no significant associations were present among 245 all the characteristics with hand-washing practices and the use of covid-19 as bioweapons. 246

247 **DISCUSSION**

In Pakistan, the combined number of persons infected with hepatitis B virus (HBV) and hepatitis 248 C virus (HCV) is over 15 million¹². Free treatment for viral hepatitis is being offered throughout 249 250 the nation thanks to the Hepatitis Prevention and Treatment Program and other governmentfunded initiatives²³. At a time when a worldwide effort to eliminate viral hepatitis was essential, 251 252 covid-19 placed a significant burden on national healthcare systems. According to Mustafa et al.²⁴ (2021), with the rise of covid-19 cases in early 2020, a sharp decline in visits of viral 253 254 hepatitis patients was observed to their respective clinics across Pakistan. However, an estimated 325 deaths because of viral hepatitis were also reported each day. The data suggested that there 255 256 was a clear shift of priority towards the Covid patients due to unavailability of a valid treatment and increased number of causalities. 257

Current study is unique as it primarily examined how the Hepatitis B and C patients residing inPeshawar KP and Muzaffarabad AJK have responded to the covid-19 immunization program.

Currently no data is available regarding concerns of hepatitis patients in the area, therefore, we have assessed the participants concerns regarding the vaccine and compared it with the other studies conducted in the world.

As described in the Health Belief Mode, the preventive actions, like getting a vaccination, 263 depend on how people see the risks of disease and how they perceive the effectiveness, benefits, 264 and costs of these actions²⁵. Pakistan and Afghanistan are two countries where nation-wide 265 immunization has always been challenging as we have seen in the case of polio eradication 266 program according to Shafique et al.²⁶ (2021). In this study it was initially decided to contact 267 maximum number of viral hepatitis patients residing in the study area. However, it was observed 268 269 that most of the patients avoid such interviews due to some reasons. Therefore, we could succeed 270 to interview around 839 patients. The survey revealed that majority of the participants (79.5%)271 were open to vaccination which shows appositive attitude towards the covid-vaccination. The 272 reason might be the easy availability of the vaccine and an active covid-19 eradication program in which healthcare workers are going door to door to make sure everyone has got vaccinated. 273 The results were even better than a similar study conducted by Tahir et al.²⁷ in 2021. 274

However, there are still number of individuals which are not immunized due to some reason which is a real concern. It is also notable that majority of the individuals who participated in this study was between the age of 18 and (57.1 %) which indicates that young generation is more open to express their opinion about health issues. There were mixed responses when the participants were asked whether a patient suffering from viral hepatitis should get immunized.

280 Most of the patients (54.7 %) refused to get fully vaccinated despite the government's strict 281 orders because they were worried about their liver condition. Unfortunately, there is not much data about the effect of covid vaccines on the liver of hepatitis B and C patients specifically. 282 283 Therefore, it is nearly impossible to persuade a person for getting a vaccination with a poor liver condition. Furthermore, there are some studies that have reported the postvaccination 284 Autoimmune Hepatitis (AIH)²⁸⁻³² which makes it essential to study the health of viral hepatitis 285 patients after vaccination to devise a better strategy for hepatitis patients in order to prevent 286 287 covid-19.

More than half of the patients (57.5 %) who refused to take the 2^{nd} dose individuals believed that 288 covid-19 vaccination might not protect them from the covid-19 infection because they got ill or 289 290 observed that people contracted infection even getting vaccinated. The concern is authentic; 291 there are many cases reported around the world where vaccines have failed to prevent individuals from the disease. For instance, in a recent study Jain et al.³³ (2021) reported that despite its 292 effectiveness in preventing masses from the adverse effects of covid infection the covid vaccine 293 294 was not proved suitable for certain individuals and postvaccination infection even deaths have been raised many questions on the efficacy of the vaccine especially in patients with 295 296 vulnerability.

There were a few participants (12.2 %) who were covid against the vaccination because they developed adverse reactions after getting the 1^{st} dose of covid vaccine. This concern was not baseless as many though rare but incidents regarding hypersensitivity reaction to covid vaccine have been reported since 2020 vaccine roll out³⁴.

301 About 218 (74.1 %) out of total participants believed that strict Standard Operating Procedures 302 (SOPs) could prevent them from infection. Their belief was not wrong as we have seen that strict 303 precautionary measures have saved masses when there was no vaccine available during the pandemic back in 2020. In random studies Kissler et al.³⁵ (2020) and Moosa³⁶ (2020) analyzed 304 305 that social distancing has appeared to be quite effective to contain the covid infection when there was no vaccine available. Similarly, Hsieh et al³⁷. 2020, reported that preventive measures such 306 as social distancing, using Personal Protective Equipment (PPE), and frequent handwashing, etc. 307 308 at a personal level could be significantly helpful to control the covid infection in the absence of other interventions. However, their approach to avoid covid-19 infection was not realistic. It is 309 impossible to avoid social contact in this fast-paced life and sometimes SOPs are not enough. It 310 is observed in various studies though minimal but there are still chances to get infected by 311 following SOPs only³⁸. 312

313 CONCLUSION

It was concluded that despite a successful covid-19 prevention program in Pakistan the concern towards the safety and efficacy of covid vaccine is still there. The study revealed that the reason to refuse vaccination cannot be neglected as they are genuine and need to be addressed carefully.

Additionally, addressing the issues regarding vaccine refusal requires genuine data demonstrating the benefits of vaccines in viral hepatitis patients is inevitable in order to resolve the ambiguity related to covid vaccination efficacy.

320 LIMITATIONS IN STUDY

Despite many efforts for making this study possible, it has a few limitations. First, the study area was confined to only two cities Peshawar and Muzaffarabad which is not enough to portray a clear picture of the current situation in Pakistan. Secondly, the resistance towards covid-19 vaccination-related reporting also makes data collection difficult. Natives especially hepatitis patients usually do not want to take part in such studies to avoid stigmatization.

326

327 **REFERENCES**

- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL,
 Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat
 origin. nature. 2020 Mar;579(7798):270-3.
- Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY,
 Yuan ML. A new coronavirus associated with human respiratory disease in China.
 Nature. 2020 Mar;579(7798):265-9.
- World Health Organization Coronavirus Disease 2019(COVID-19) Situation Report-97.
 Available from: <u>https://www.who.int/docs/default-source/coronaviruse/situation-</u>
 reports/20200426-sitrep-97-covid-19.pdf.
- 4. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio Medica: Atenei
 Parmensis. 2020;91(1):157.
- 5. Liao M, Liu H, Wang X, Hu X, Huang Y, Liu X, Brenan K, Mecha J, Nirmalan M, Lu
 JR. A technical review of face mask wearing in preventing respiratory COVID-19
 transmission. Current Opinion in Colloid & Interface Science. 2021 Apr 1;52:101417.
- 6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T.
 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus

pneumonia in Wuhan, China: a descriptive study. The lancet. 2020 Feb
15;395(10223):507-13.

- Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, Genescà J,
 Gill US, James TW, Jones PD, Marshall A. High mortality rates for SARS-CoV-2
 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary
 results from an international registry. Journal of hepatology. 2020 Sep 1;73(3):705-8.
- Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y.
 Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
 The Lancet respiratory medicine. 2020 Apr 1;8(4):420-2.
- Baroiu L, Anghel L, Tatu AL, Iancu AV, Dumitru C, Le□e AC, Drăgănescu M, Năstase
 F, Nicule□ E, Fotea S, Nechita A. Risk of hepatitis B reactivation: From biologic
 therapies for psoriasis to immunosuppressive therapies for COVID-19. Experimental and
 Therapeutic Medicine. 2022 Jun 1;23(6):1-9.
- 10. Ronderos D, Omar AM, Abbas H, Makker J, Baiomi A, Sun H, Mantri N, Choi Y,
 Fortuzi K, Shin D, Patel H. Chronic hepatitis-C infection in COVID-19 patients is
 associated with in-hospital mortality. World Journal of Clinical Cases. 2021 Oct
 10;9(29):8749.
- 11. CGHE (2022). National Hepatitis Elimination Profile for Pakistan: Key Takeaways,
 National Hepatitis Elimination Profile for Pakistan: Key Takeaways | Coalition for
 Global Hepatitis Elimination. The Coalition for Global Hepatitis Elimination (CGHE).
 Available at: https://www.globalhep.org/news/national-hepatitis-elimination-profilepakistan-key-takeaways (Accessed: October 28, 2022).
- 12. Kazmi SA, Rauf A, Shafique F, Asim N, Hassan MU. Kashmiri refugees at the verge of
 hepatitis B and C epidemic in the State of Azad Jammu and Kashmir, Pakistan. Revista
 de Saúde Pública. 2022 May 6;56.
- 369 13. WHO (2022) Vaccines and immunization, World Health Organization. World Health
 370 Organization. Available at: https://www.who.int/health-topics/vaccines-and 371 immunization#tab=tab_1 (Accessed: October 29, 2022).
- 14. Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. Vaccines, new opportunities for a
 new society. Proceedings of the National Academy of Sciences. 2014 Aug
 26;111(34):12288-93.

- 375 15. Bärnighausen T, Bloom DE, Cafiero-Fonseca ET, O'Brien JC. Valuing vaccination.
 376 Proceedings of the National Academy of Sciences. 2014 Aug 26;111(34):12313-9.
- 16. Public Health England, Cambridge University MRC Biostatistics Unit. Direct and
 indirect impact of the vaccination programme on COVID-19 infections and mortality.
- 379 17. Galvani A, Moghadas SM, Schneider EC. Deaths and hospitalizations averted by rapid
 380 US vaccination rollout. The Commonwealth Fund. Issue Briefs. 2021 Jul 7.
- 18. Government of Pakistan 2022. Covid-19 health advisory platform by Ministry of
 National Health Services Regulations and Coordination (2022) COVID. Available at:
 https://covid.gov.pk/stats/pakistan (Accessed: October 28, 2022).
- 19. Hashim, A. (2021). Vaccine hesitancy in Pakistan heightens risk of COVID resurgence.
 Al Jazeera.
- 20. Weibel, C. (2021) Pakistan steps up COVID-19 vaccine roll-out, UNICEF Pakistan.
 Available at: https://www.unicef.org/pakistan/stories/pakistan-steps-covid-19-vaccineroll-out (Accessed: October 27, 2022).
- 389 21. Barello S, Nania T, Dellafiore F, Graffigna G, Caruso R. 'Vaccine hesitancy'among
 390 university students in Italy during the COVID-19 pandemic. European journal of
 391 epidemiology. 2020 Aug;35(8):781-3.
- 22. Abdulsattar, B. (2021) Ipsos survey on vaccine hesitancy in Pakistan 9th March 2021.
 Ipsos. Available at: https://www.ipsos.com/en-pk/ipsos-survey-vaccine-hesitancy pakistan-9th-march-2021 (Accessed: October 27, 2022).
- 23. Khan A, Afzal S, Yaqoob A, Fatima R, Haq MU, Junaid K, Nadir A. Epidemiology of
 viral hepatitis B and C in Punjab, Pakistan: a multicenter cross-sectional study, 2017-18.
 F1000Research. 2019 Dec 6;8(2065):2065.
- 24. Mustafa ZU, Kow CS, Hasan SS. Effect of COVID-19 on viral hepatitis services in
 Pakistan. The Lancet Gastroenterology & Hepatology. 2021 Mar 1;6(3):163-4.
- 400 25. Janz NK, Becker MH. The health belief model: A decade later. Health education
 401 quarterly. 1984 Mar;11(1):1-47.
- 26. Shafique F, Nayab H, Asim N, Akbar N, Shafi N, Manzoor S, Eeden FV, Ali S. Attitude
 and perception towards vaccination against poliomyelitis in Peshawar, Pakistan. Revista
 de Saúde Pública. 2021 Dec 8;55:104.

- 27. Tahir MJ, Saqlain M, Tariq W, Waheed S, Tan SH, Nasir SI, Ullah I, Ahmed A.
 Population preferences and attitudes towards COVID-19 vaccination: a cross-sectional
 study from Pakistan. BMC public health. 2021 Dec;21(1):1-2.
 <u>https://doi.org/10.1186/s12889-021-11814-5</u>
- 28. Palla P, Vergadis C, Sakellariou S, Androutsakos T. Autoimmune hepatitis after
 COVID 19 vaccination: A rare adverse effect?. Hepatology (Baltimore, Md.). 2022
 Feb;75(2):489.
- 29. Camacho-Domínguez L, Rodríguez Y, Polo F, Gutierrez JC, Zapata E, Rojas M, Anaya
 JM. COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and
 review of the literature. Journal of translational autoimmunity. 2022 Jan 4:100140.
- 30. Bril F, Al Diffalha S, Dean M, Fettig DM. Autoimmune hepatitis developing after
 coronavirus disease 2019 (COVID-19) vaccine: causality or casualty?. Journal of
 Hepatology. 2021 Jul 1;75(1):222-4.
- 31. Garrido, I., Lopes, S., Simões, M.S., Liberal, R., Lopes, J., Carneiro, F. and Macedo, G.,
 2021. Autoimmune hepatitis after COVID-19 vaccine–more than a coincidence. Journal
 of Autoimmunity, 125, p.102741.
- 32. Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera□de la Tijera F, Aloman C, Rıza
 Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM. Outcome of COVID□19 in
 patients with autoimmune hepatitis: an international multicenter study. Hepatology. 2021
 Jun;73(6):2099-109.
- 33. Jain VK, Iyengar KP, Ish P. Elucidating causes of COVID-19 infection and related deaths
 after vaccination. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021
 Sep 1;15(5):102212.
- 428 34. Fernandez-Davila N, Taylor MG, Anvari S. Hypersensitivity Reactions to COVID-19
 429 Vaccines—Identify High-Risk Children and Vaccinate the Rest. JAMA pediatrics. 2022
 430 May 1.
- 35. Kissler S, Tedijanto C, Lipsitch M, Grad YH. Social distancing strategies for curbing the
 COVID-19 epidemic. MedRxiv. 2020 Jan 1.
- 36. Moosa IA. The effectiveness of social distancing in containing Covid-19. Applied
 Economics. 2020 Dec 13;52(58):6292-305.

- 37. Hsieh CC, Lin CH, Wang WY, Pauleen DJ, Chen JV. The outcome and implications of
 public precautionary measures in Taiwan–Declining respiratory disease cases in the
 COVID-19 pandemic. International journal of environmental research and public health.
 2020 Jul;17(13):4877.
 Avouni L Maatoug L Dhouib W. Zammit N. Fradi SP. Chammam P. Channem H.
- 439 38. Ayouni I, Maatoug J, Dhouib W, Zammit N, Fredj SB, Ghammam R, Ghannem H.
- 440 Effective public health measures to mitigate the spread of COVID-19: a systematic 441 review. BMC public health. 2021 Dec;21(1):1-4.

442 **<u>Tables:</u>**

443 Table 2-show demographic data frequencies of the participants. (n = 839).

No.	Demographic variables	Number	Percentage (%)					
		(n)						
1	Age (years)							
	18-30	479	57.1					
	31-40	164	19.5					
	41-55	151	18.0					
	56->65	45	5.4					
2	Gender							
	Male	536	63.9					
	Female	303	36.1					
3	Qualification		L					
	Nil	79	9.4					
	Primary	50	6.0					
	Secondary	49	5.8					
	Intermediate	86	10.3					
	Graduate	329	39.2					
	Post-graduate	246	29.3					
4	Employment status							
	Unemployed or Housewives	211	25.1					
	Students	83	9.9					
	Paid-employed	289	34.4					
	Self-employed	256	30.5					
5	Monthly Income (PKR)							
	< 30,000	513	61.1					
	> 30,000	326	38.9					
6	Ethnicity							
	Pathan	405	48.3					
	Kashmiri	353	42.1					
	Punjabi	64	7.6					
	others	17	2.0					
7	Location		1					
	Peshawar KPK	432	51.5					
	Muzaffarabad AJK	407	48.5					

8	Hepatitis B positive

a. Question Statements

	No	436	52.0
	Yes	403	48.0
9	Hepatitis C positive	I	
	No	403	48.0
	Yes	436	52.0
10	Covid-19 vaccination		
	No	298	35.5
	Yes	541	64.5

444

445 Table 2- Commercially available Vaccines approved by the Government of Pakistan.

Approved Vaccines	Type of vaccine
Moderna mRna 1273	RNA
Pfizer/BioNTech BNT 162b2	RNA
Consino Ad5-NCov	Non-Replicating viral Vector
Gamaleya Spuntik V	Non-Replicating viral Vector
Oxford /Astrazeneca AZD1222	Non-Replicating viral Vector

446 Table 3a. Assessment of patients choosing COVID-19 vaccine for protection. Table 2B. Question

447 statements to assess Hepatitis patient for refusing COVID-19 vaccine.

Part A: Why should a hepatitis B or C positive should take Covid-19	Responses (n=839)
Vaccine?	

	No. of participants responded "Yes"	Percentage
I think there is no harm in taking Covid-19 vaccine.	477	72.4%
I believe Covid-19 vaccination will be useful in protecting the Covid-19 infection	507	76.9%
Covid-19 vaccine is available free of cost.	524	79.5%
My healthcare professionals and doctors has recommended me	469	71.2%
I believe that the benefits of COVID-19 vaccine are more than the risk involved	415	63.0%
I believe that taking Covid-19 vaccine is social responsibility	435	66.0%
There is sufficient data regarding the vaccine safety and efficacy released by the government.	374	56.8%
Many other hepatitis B and C are taking COVID-19 Vaccine	504	76.5%

b. Question Statements

	Responses (n=294)								
Part B: Reason to refuse COVID-19 vaccine	No. of patients responded "Yes"	Percentage							
I think that it will damage my liver more.	161	54.7 %							
I think that COVID-19 vaccine will affect my hepatitis therapy	181	61.5 %							
I think that strict SOPs can make me prevent from infection.	218	74.1 %							
I do not have enough information about the vaccine.	186	63.2 %							
I am against vaccine in general.	158	53.7 %							
Due to previous infection with COVID-19, I don't need vaccine	172	58.5 %							
People still got covid infection after getting vaccine.	169	57.5 %							
After getting first dose I developed some allergic reactions	36	12.2%							

448

Table 4a. Correlation between different variables of Hepatitis B and C patients with the Covid-19
 vaccine approval or rejection. b. Spearman correlation between different variables and COVID-19
 vaccine.

452

a.																			
Variables	Gender	ed uc a	tion	location	income	Occ	Occupation		Ethnicity		Hepatitis B		atitis C	Covi	Covid vaccine		2nd dose	e COV booster	
Age	1 0.124	Z	-0.126	V .03	3 📈 0.0	16 📈	-0.03	2	0.004	ž	-0.126	介	0.126	Z	0.033	Ŗ	-0.015	介	0.07
Gender		合	0.064	-0.05	5 📈 -0.0	95 个	0.057	К	0.025	Ŗ	-0.08	介	0.087	Ŗ	-0.018	合	0.093	К	-0.046
education				-0.13.	-0.0	41 📈	0.023	合	0.05	合	0.081	7	-0.081	合	0.09		0.182	5	-0.005
location					1 0.0	58 🜽	0.009	7	0.034	7	-0.06	企	0.06	∇	-0.022	î	0.048	î	0.094
income							0.044	î	0.095	î	0.075	2	-0.075	2	-0.119	<u> </u>	-0.106	î	0.083
Occupation								î	0.082	4	0.007	4	-0.007	Î	0.104	Î	0.07	î	0.103
Ethnicity					-			-			0.03		-0.03	4	-0.064	Ĩ	0.083	<u> </u>	0.044
HepatitisB					1	_						\$	-1	4	0.041	ŗ	0.096	4	0.006
Hepatitisc														\sim	-0.041	\leq	-0.096	5	-0.006
COV 2nd dose																Ц	0.394		0.028
b.				1															01200
Variable	s			Spearma	n Corre	latio	n r]	P Value (0.05)				
Age			(0.033										0.340					
Gender				-0.018										0.612					
Education	1		(0.064										0.064					
Location				-0.022										0.522					
Income				119										().001*	*			
Occupation .107										0.002**									
Ethnicity -0.035												0.309							
Hepatitis B 0.041												(0.240						
Hepatitis	С			-0.041										().240				

453

Figures:



456 Figure 2a. No. of patients receiving Covid vaccines from approved pharmaceuticals. b. No. of

Patients refused to get immunized.